Wednesday, March 05, 2025 | 03:06 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

USFDA approves Glycopyrrolate ANDA filed from Indoco's Goa Plant II

Image

Capital Market
Indoco Remedies announced that Abbreviated New Drug Application (ANDA) for Glycopyrrolate Injection 0.2 mg/ml filed from Indoco's Goa Plant II on behalf of its partner in the US, has been approved by the United States Food & Drug Administration (USFDA).

Glycopyrrolate is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions. The market size of this product in the US is US$ 120 million.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 01 2019 | 12:39 PM IST

Explore News